FGF9 activated FGFR1 signaling in a dose-dependent manner within 15 minutes in DU 145 prostate cancer cells (Supplemental Figure 4, C and D), as indicated by the phosphorylation of ERK and FRS2. This evidence concerns the gene FRS2 and prostate carcinoma.